Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Novartis, Cerulean Team To Develop Nanoparticle-Drug Conjugates

Executive Summary

Leveraging the brain power behind the first approved IPF drug, Esbriet, small companies Antegrin and Cascadia merge to form the fibrosis-centered Indalo Therapeutics. Gedeon Richter in-licenses a biosimilar of Roche’s Herceptin.

Advertisement

Related Content

Cerulean Shifts From Ovarian Cancer To Contraceptives In Reverse Merger With Daré
Start-Up Quarterly Statistics, Q4 2016
AbbVie Knocks Back Ablynx's Vobarilizumab In RA
Sun Dips Toe Into Vaccines With Dengvaxia Challenge
ASLAN Refills Pipeline With Homegrown Immuno-Onc Asset
Cerulean Slashes Jobs After Phase II Kidney Cancer Failure
European Notebook: All Change In The C-Suites; EMA PRIME Starts; French Experts Recommend Phase I Changes
Hanmi’s Roll Continues With ZAI China Cancer Deal
ZAI Builds On Sanofi Ties For Lung Cancer Candidate
INTERVIEW: Dong-A Seeks Partners For Global Expansion Push

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097521

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel